Followers | 88 |
Posts | 5699 |
Boards Moderated | 1 |
Alias Born | 07/06/2014 |
Thursday, September 26, 2024 8:24:50 AM
Recent KTTA News
- Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer • GlobeNewswire Inc. • 11/20/2024 12:02:00 PM
- Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 09/26/2024 10:44:51 PM
- Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer • GlobeNewswire Inc. • 09/26/2024 11:02:00 AM
- Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies • GlobeNewswire Inc. • 09/09/2024 12:01:00 PM
- Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board • GlobeNewswire Inc. • 09/03/2024 12:02:00 PM
- Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 08/28/2024 01:11:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:30:35 PM
- Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial • GlobeNewswire Inc. • 06/13/2024 10:59:00 AM
- Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/28/2024 10:59:00 AM
- Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 04/29/2024 11:59:00 AM
- Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers • GlobeNewswire Inc. • 04/24/2024 11:59:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:46:21 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:46:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:45:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/02/2024 02:45:23 AM
- Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 • GlobeNewswire Inc. • 02/13/2024 12:59:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:30:41 PM
- Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position • GlobeNewswire Inc. • 01/08/2024 12:59:00 PM
Basanite, Inc. to Open New Production and Distribution Facility in Northeast Ohio • BASA • Jan 2, 2025 8:28 AM
The Crypto Company Highlights Blockchain Training Alliance's Successes and Momentum for 2025 • CRCW • Dec 26, 2024 8:58 AM
Hertz Energy Provides Antimony and Critical Minerals Projects Update and Announces Financing • HZLIF • Dec 20, 2024 9:00 AM
North Bay Resources Announces Arrival of 42 Tons Gold Ore at Bishop Gold Mill, California • NBRI • Dec 20, 2024 9:00 AM
Consumer Automotive Finance Subsidiary Drago Knives Narrows Down Potential Partner to Manufacture Patented Throwing Knives • CAFI • Dec 20, 2024 9:00 AM
$ASNS - Is this the Next Big Cybersecurity Stock? How Actelis Networks is Revolutionizing Critical Infrastructure Protection • ASNS • Dec 20, 2024 8:50 AM